|
|
||||||||
ORIGINAL RESEARCH |
From the Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland; and Medix Biochemica, Kauniainen, Finland.
Address reprint requests to: Mika Nuutila, MD Department of Obstetrics and Gynecology Helsinki University Central Hospital Haartmaninkatu 2, PO Box 140 FIN-00029 HUCH Finland E-mail: mika.nuutila{at}huch.fi
Objective: To study the isoforms of insulin-like growth factor binding protein-1 (IGFBP-1) in cervical secretion and to evaluate whether their assessment could serve in prediction of cervical ripeness at term.
Methods: We measured the concentrations of IGFBP-1 in cervical swab samples of 64 women scheduled for labor induction by amniotomy or cervical ripening with prostaglandin E2 gel. Two immunoenzymometric assays were used: a previously described assay 1, which detects the nonphosphorylated and lesser phosphorylated isoforms, and a novel assay 2, which detects the lesser and highly phosphorylated isoforms of IGFBP-1. A set of 39 amniotic fluid (AF) samples also was analyzed to compare the phosphorylation status of IGFBP-1 in cervical secretion with that in AF.
Results: In all cervical samples, IGFBP-1 concentration was higher by assay 2 than by assay 1, whereas in all AF samples, the results were the opposite. Initially, the median IGFBP-1 concentration in the ripe cervices (Bishop scores 6 or greater; n = 29) was approximately four times as high as that in the unripe cervices (Bishop scores 5 or less; n = 35). The cervical IGFBP-1 concentrations increased eight-fold in 6 hours after the first application of PGE2.
Conclusion: Phosphorylated isoforms of IGFBP-1, different from those in AF, are present in the cervical secretion of women with intact fetal membranes and reflect cervical ripeness. A bedside test for those IGFBP-1 isoforms might help in predicting amenability for labor induction.
This article has been cited by other articles:
![]() |
H. Honkanen, E.-M. Rutanen, and O. Heikinheimo Differential kinetics of serum and cervical insulin-like growth factor-binding protein-1 during mifepristone-misoprostol-induced medical termination of early pregnancy Mol. Hum. Reprod., January 1, 2004; 10(1): 65 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kajantie, L. Dunkel, E.-M. Rutanen, M. Seppala, R. Koistinen, A. Sarnesto, and S. Andersson IGF-I, IGF Binding Protein (IGFBP)-3, Phosphoisoforms of IGFBP-1, and Postnatal Growth in Very Low Birth Weight Infants J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2171 - 2179. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Frost, G. J. Nystrom, and C. H. Lang Stimulation of Insulin-Like Growth Factor Binding Protein-1 Synthesis by Interleukin-1{beta}: Requirement of the Mitogen-Activated Protein Kinase Pathway Endocrinology, September 1, 2000; 141(9): 3156 - 3164. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |